🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Incredibly proud to celebrate Rasha Al-Lamee being awarded the Global CV Future Leader Award 2024 #GCVAwards. An exceptional mentor to us, who has also built a strong team of young researchers at Imperial College Matthew Shun-Shin Christopher Rajkumar Michael Foley Florentina Simader Shayna Chotai

Goodbye #ACC from the ORBITA team. Thank you for featuring our work and see you again next year! Florentina Simader Shayna Chotai Michael Foley Christopher Rajkumar Fiyyaz Ahmed-Jushuf Matthew Shun-Shin

Delighted to bring our EAPCI Journal club to 🇬🇧 Discussing #ORBITA2 and the fantastic work by the team: Rasha Al-Lamee Christopher Rajkumar Michael Foley Fiyyaz Ahmed-Jushuf Florentina Simader Prof Darrel Francis ☺ Mk CardioFellows Great Again

Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint JAMA Surgery We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful Rasha Al-Lamee Katie Thomas NHLI jamanetwork.com/journals/jamas…

Impact not impact factor - a new vision from Harlan Krumholz for the new #JACC

…and this: O R B I T A 2: symptom-stratified analysis ⏰ 15/05 8:30 📍 Theatre Havane 👋 Florentina Simader Rasha Al-Lamee

#EuroPCR #JACC LBCT SimPub: #ORBITA-2 symptom-stratified analysis - Although symptom severity & nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of #PCI. bit.ly/3QK76cj Florentina Simader Rasha Al-Lamee

🔥 Important new insights from ORBITA-2 study presented today at #EuroPCR 👉🏼 More angina symptoms do not necessarily reflect more extended coronary disease 👉🏼 The clinical history is a strong predictor of the efficacy of PCI 🚨Interroge your patients! PCRonline 🫀 Rasha Al-Lamee

The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in JACC Journals by Florentina Simader and Christopher Rajkumar. PCI isn’t a therapy for all symptoms, it’s a therapy for angina Rasha Al-Lamee Matthew Shun-Shin

#ICYMI Aaysha Cader asked Rasha Al-Lamee & Florentina Simader to summarize the symptom-stratified analysis of ORBITA-2 presented at #EuroPCR!

.Florentina Simader on #ORBITA-2 at #EuroPCR: 📌Poor correlation between symptoms & disease severity 📌Symptom nature is a powerful predictor of the placebo-controlled efficacy of #PCI 📌Rose angina & typical angina are excellent predictors of the placebo-controlled efficacy of PCI

So grateful and proud to have such an incredible mentor and role model Rasha Al-Lamee ✨

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response Rasha Al-Lamee Florentina Simader tctmd.com/news/orbita-2-…

#cvCAD patients who have angina are more likely to achieve symptom relief from #PCI, according to an analysis of the ORBITA-2 trial in #JACC. bit.ly/3V3K3LW TCTMD Caitlin E. Cox

Merci Paris and #euroPCR for an incredible week and experience with the best Team and colleagues✨ Rasha Al-Lamee JACC Journals PCRonline 🫀

Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Another n-of-1 trial that might have some interesting results. Well done Shayna Chotai on achieving the first of many big milestones during your PhD!

Watch This Week's Episode of OPCI Journal Club: “ORBITA-STAR Trial and the ORBITA II Symptoms Analysis” presented by Rasha Al-Lamee Christopher Rajkumar and Florentina Simader. Joined by panelists David J. Cohen, MD, MSc Dr. Jeffrey W. Moses Evan Shlofmitz and Dr. Lawrence Garcia. opci.live/journal-club/ #cardiotwitter

🔥🔥🔥

Michael foley presenting orbita 2 analysis showing that ffr and ifr predict angina benefit from pci. Absolute values matter more than dichotimous cutoff. I would personally like to see how microvascular function fits into this Rasha Al-Lamee MIЯVΛƬ #IC Omar Khalique Hany Ragy